The Hoover Institution Establishes New Initiative and Names Senior Fellow to Study Immigration
STANFORD, Calif., Nov. 8, 2024 /PRNewswire/ — The Hoover Institution at Stanford University is pleased to announce a new research…
Artificial Intelligence Market to Grow by USD 237.4 Billion from 2024-2028, as AI-Driven Fraud Prevention and Malicious Attack Protection Boost Market – Technavio
NEW YORK, Nov. 8, 2024 /PRNewswire/ — Report with market evolution powered by AI – The global artificial intelligence (AI)…
BayCare Celebrates Its Teams’ Dedication During Hurricanes
CLEARWATER, Fla., Nov. 8, 2024 /PRNewswire/ — BayCare salutes its team members and all first responders in a new commercial…
ParkerVision Files U.S. Supreme Court Cert. Petition Challenging Federal Circuit’s Practice of Summarily Affirming Patent Agency Appeals
With Inventors’ Rights on the Line, ParkerVision’s Petition Seeks Adequate Process for Patent Holders Across the U.S. NEW YORK, Nov.…
Shincheonji’s Zion Christian Mission Center Holds Graduation of 111,628
ANAHEIM, Calif., Nov. 8, 2024 /PRNewswire/ — Shincheonji Church of Jesus held the ‘Zion Christian Mission Center 115th Class 110,000…
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of iLearningEngines
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In iLearningEngines To…
Do China and the U.S. have common interests?
BEIJING, Nov. 8, 2024 /PRNewswire/ — A news report by China.org.cn on China-US relations: No doubt they do. First, when…
Greenway’s Cell-Driven “Core” Technology Debuts at the Milan EICMA Two-Wheeler Exhibition
MILAN, Nov. 8, 2024 /PRNewswire/ — November 5th to 10th, Greenway(SHSE:688345), a global leader in micromobility lithium battery solutions , showcased…
Fortune Names Viettel as a Leading Company for Positive Social Impact
HANOI, Vietnam, Nov. 8, 2024 /PRNewswire/ — In Fortune’s “Change the World 2024” rankings, Viettel Group ranks 3rd among over 50…
TEZSPIRE MET BOTH CO-PRIMARY ENDPOINTS IN PHASE 3 TRIAL FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPS
Statistically Significant Reduction in Nasal Polyp Size, Nasal Congestion Compared to Placebo THOUSAND OAKS, Calif., Nov. 7, 2024 /PRNewswire/ —…
↑